Evaluation of Rifalazil in a Combination Treatment Regimen as an Alternative to Isoniazid-Rifampin Therapy in a Mouse Tuberculosis Model
The newer rifamycin, rifalazil (RLZ) (previously known as KRM-1648), has been shown in prior experiments to be a highly potent drug against Mycobacterium tuberculosis. In this report, we studied the efficacy of RLZ in combination with pyrazinamide (PZA) and ethambutol (EMB) in a long-term in vivo ex...
Shranjeno v:
| izdano v: | Antimicrob Agents Chemother |
|---|---|
| Principais autores: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
American Society for Microbiology (ASM)
2000
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC101623/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/11036043/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.44.11.3167-3168.2000 |
| Oznake: |
Brez oznak, prvi označite!
|